Albert Garcia-Romeu
Biographic Data
| ID | 231672 |
|---|---|
| NAME | Albert Garcia-Romeu |
| GIVEN NAMES | Albert |
| FAMILY NAME | Garcia-Romeu |
| SIGNATURE | GARCIA-ROMEU A |
| AFFILIATIONS | Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
| VERIFIED | No |
| TOTAL WORKS | 13 |
| TOTAL CITATIONS | 4 |
| AUTHOR COUNT | 13 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
Setting, context and the regulatory atmospheres of psychedelic medicine
The revival of psychedelic medicalization is often narrated as a story of scientific legitimacy and neurotherapeutic promise, yet the unusual sensitivity of psychedelics to environmental conditions has encouraged research on music, therapy, setting, and other contextual factors. Treating setting and context as the building blocks of felt atmospheres, this article examines how regulation actively shapes atmospheres of consumption for substances th…
Methamphetamine use and HIV prevention: A qualitative study on challenges and opportunities for PrEP utilization
Methamphetamine use often co-occurs with sexual behaviors that may increase HIV acquisition risk and disrupt adherence to HIV pre-exposure prophylaxis (PrEP). To explore barriers and opportunities for PrEP among people who use methamphetamine, we conducted semi-structured interviews with 28 self-reported HIV-negative adults (ages 18–55) with current moderate-to-high risk methamphetamine use in the New York City metropolitan area. Transcripts were…
Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis
Seeing the forest for the trees: An ecological systems theory approach to addressing emergent issues in psychedelic-assisted therapy research
Despite growing interest in psychedelic-assisted therapy (PAT) research, there remains a lack of consensus about key issues relevant to difficulties in predicting acute drug effects, and the role of therapeutic support in clinical trials. In the absence of a clear theoretical model to conceptualize multifaceted components in PAT research, dialogue across contexts (e.g., popular media, peer reviewed journals, conference settings) is becoming incre…
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective, longitudinal survey
Results from this study, the largest prospective survey of naturalistic psilocybin use to date, support the potential for psilocybin to produce lasting improvements in mental health symptoms and general wellbeing
Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine
Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs
Current and Future Potential Impact of Covid-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use
Kratom ( Mitragyna speciosa Korth., Rubiaceae) is native to and has traditional use in Southeast Asia. The number of kratom users outside of Southeast Asia has increased significantly in recent decades with use spreading to the Unites States (US) and Europe. Because of its reputed opioid-like psychoactive effects at higher doses, kratom has been regulated in several countries and is subject to an import ban by the US Food and Drug Administration.…
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
BACKGROUND: Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. AIMS: The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long…
Long-term follow-up of psilocybin-facilitated smoking cessation
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated sm…
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy (CBT) for smoking cessation. Twelve of 15 participan…
Self-transcendent experience: A Grounded Theory Study
Current theories in psychology conceptualize self-transcendence as a personality trait, a developmental construct, and a particular class of anomalous experience. Despite extensive research on self-transcendence, the process, outcomes, and nature of self-transcendent experience (STE) remain elusive. This study focused on the self-reported narratives of STE in 15 healthy adults. Accounts were collected in face-to-face interviews, transcribed, and …
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protoc…
Self-transcendent experience: A Grounded Theory Study
Current theories in psychology conceptualize self-transcendence as a personality trait, a developmental construct, and a particular class of anomalous experience. Despite extensive research on self-transcendence, the process, outcomes, and nature of self-transcendent experience (STE) remain elusive. This study focused on the self-reported narratives of STE in 15 healthy adults. Accounts were collected in face-to-face interviews, transcribed, and …
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protoc…
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the context of cognitive behavioral therapy (CBT) for smoking cessation. Twelve of 15 participan…
Self-transcendent experience: A Grounded Theory Study
Current theories in psychology conceptualize self-transcendence as a personality trait, a developmental construct, and a particular class of anomalous experience. Despite extensive research on self-transcendence, the process, outcomes, and nature of self-transcendent experience (STE) remain elusive. This study focused on the self-reported narratives of STE in 15 healthy adults. Accounts were collected in face-to-face interviews, transcribed, and …
Long-term follow-up of psilocybin-facilitated smoking cessation
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated sm…
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
BACKGROUND: Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen participants completed a psilocybin-facilitated smoking cessation pilot study between 2009 and 2015. AIMS: The aims of this study were as follows: (1) to identify perceived mechanisms of change leading to smoking cessation in the pilot study; (2) to identify key themes in participant experiences and long…
Current and Future Potential Impact of Covid-19 on Kratom (Mitragyna speciosa Korth.) Supply and Use
Kratom ( Mitragyna speciosa Korth., Rubiaceae) is native to and has traditional use in Southeast Asia. The number of kratom users outside of Southeast Asia has increased significantly in recent decades with use spreading to the Unites States (US) and Europe. Because of its reputed opioid-like psychoactive effects at higher doses, kratom has been regulated in several countries and is subject to an import ban by the US Food and Drug Administration.…
Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs
Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective, longitudinal survey
Results from this study, the largest prospective survey of naturalistic psilocybin use to date, support the potential for psilocybin to produce lasting improvements in mental health symptoms and general wellbeing
Seeing the forest for the trees: An ecological systems theory approach to addressing emergent issues in psychedelic-assisted therapy research
Despite growing interest in psychedelic-assisted therapy (PAT) research, there remains a lack of consensus about key issues relevant to difficulties in predicting acute drug effects, and the role of therapeutic support in clinical trials. In the absence of a clear theoretical model to conceptualize multifaceted components in PAT research, dialogue across contexts (e.g., popular media, peer reviewed journals, conference settings) is becoming incre…
Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis
Setting, context and the regulatory atmospheres of psychedelic medicine
The revival of psychedelic medicalization is often narrated as a story of scientific legitimacy and neurotherapeutic promise, yet the unusual sensitivity of psychedelics to environmental conditions has encouraged research on music, therapy, setting, and other contextual factors. Treating setting and context as the building blocks of felt atmospheres, this article examines how regulation actively shapes atmospheres of consumption for substances th…
Methamphetamine use and HIV prevention: A qualitative study on challenges and opportunities for PrEP utilization
Methamphetamine use often co-occurs with sexual behaviors that may increase HIV acquisition risk and disrupt adherence to HIV pre-exposure prophylaxis (PrEP). To explore barriers and opportunities for PrEP among people who use methamphetamine, we conducted semi-structured interviews with 28 self-reported HIV-negative adults (ages 18–55) with current moderate-to-high risk methamphetamine use in the New York City metropolitan area. Transcripts were…
Psychedelics and Drug Studies (11 works) · Psychology (9 works) · Medicine (8 works) · Psychiatry (8 works) · Hallucinogen (7 works) · Psilocybin (7 works) · Chemical synthesis and alkaloids (6 works) · Clinical Psychology (5 works) · Addiction (4 works) · Psychotherapist (4 works)